Published by: Kowsar

Prograf Concentrations in Liver Transplantation: Correlation With Headache and Other Neurotoxic Complications?

Zahra Tolou-Ghamari 1 , * and Behnam Sanei 2
Authors Information
1 Isfahan Urology and Renal Transplantation Research Center, Al-Zahra Research Centers, Isfahan University of Medical Sciences, Isfahan, IR Iran
2 Department of General Surgery, Saint Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, IR Iran
Article information
  • Thrita: March 01, 2016, 5 (1); e32670
  • Published Online: January 23, 2016
  • Article Type: Research Article
  • Received: August 25, 2015
  • Revised: September 22, 2015
  • Accepted: September 29, 2015
  • DOI: 10.5812/thrita.32670

To Cite: Tolou-Ghamari Z, Sanei B. Prograf Concentrations in Liver Transplantation: Correlation With Headache and Other Neurotoxic Complications?, Thrita. 2016 ;5(1):e32670. doi: 10.5812/thrita.32670.

Copyright © 2016, Thrita. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Kim JM, Kwon CH, Joh JW, Sinn DH, Lee S, Choi GS, et al. The Conversion of Once-daily Extended-release Tacrolimus is Safe in Stable Liver Transplant Recipients: A Randomized Prospective Study. Liver Transpl. 2015; [DOI][PubMed]
  • 2. Suh KS, Kim T, Yi NJ, Hong G. Preparation for high altitude expedition and changes in cardiopulmonary and biochemical laboratory parameters with ascent to high altitude in transplant patients and live donors. Clin Transplant. 2015; 29(11): 1013-20[DOI][PubMed]
  • 3. Tolou-Ghamari Z. Monitoring Tacrolimus (FK506) in Liver Transplant Recipients: A Consideration of Alternative Techniques and the Influence of Clinical Status. 1999;
  • 4. Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation. 1994; 57(4): 519-25[PubMed]
  • 5. Fung JJ, Alessiani M, Abu-Elmagd K, Todo S, Shapiro R, Tzakis A, et al. Adverse effects associated with the use of FK 506. Transplant Proc. 1991; 23(6): 3105-8[PubMed]
  • 6. Kahan BD. The evolution of therapeutic immunosuppression and the potential impact of drug concentration monitoring. Ther Drug Monit. 1995; 17(6): 560-3[PubMed]
  • 7. Peddi VR, Demmy AM, Munda R, Alexander JW, First MR. Tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Transplant Proc. 1998; 30(2): 509-11[PubMed]
  • 8. Yang TH, Chen YK, Xue F, Han LZ, Shen CH, Zhou T, et al. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation. Int J Clin Pract Suppl. 2015; 183: 53-62[DOI][PubMed]
  • 9. Sikma MA, van Maarseveen EM, van de Graaf EA, Kirkels JH, Verhaar MC, Donker DW, et al. Pharmacokinetics and Toxicity of Tacrolimus Early After Heart and Lung Transplantation. Am J Transplant. 2015; 15(9): 2301-13[DOI][PubMed]
  • 10. Staatz CE, Tett SE. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Clin Pharmacokinet. 2015; 54(10): 993-1025[DOI][PubMed]
  • 11. Snell GI, Ivulich S, Mitchell L, Westall GP, Levvey BJ. Evolution to twice daily bolus intravenous tacrolimus: optimizing efficacy and safety of calcineurin inhibitor delivery early post lung transplant. Ann Transplant. 2013; 18: 399-407[DOI][PubMed]
  • 12. O'Regan JA, Canney M, Connaughton DM, O'Kelly P, Williams Y, Collier G, et al. Tacrolimus trough-level variability predicts long-term allograft survival following kidney transplantation. J Nephrol. 2015; [DOI][PubMed]
  • 13. Arnold R, Pussell BA, Pianta TJ, Lin CS, Kiernan MC, Krishnan AV. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients Am J Transplant 2013; 13(9): 2426-32[PubMed]
  • 14. Moscato D, Nonnato A, Adamo R, Vancheri M, Caropreso A. Therapeutic monitoring of tacrolimus: aberrant results by an immunoassay with automated pretreatment. Clin Chim Acta 2010; 411(1-2): 77-80[PubMed]
  • 15. Penninga L, Penninga EI, Moller CH, Iversen M, Steinbruchel DA, Gluud C. Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. Cochrane Database Syst Rev. 2013; 5[DOI][PubMed]
  • 16. Yamaguchi K, Fukuoka N, Kimura S, Shinohara N, Tatsumichi T, Tai T, et al. [Case of encephalopathy seemingly caused by tacrolimus at blood concentration near the upper limit of therapeutic range]. Yakugaku Zasshi. 2012; 132(7): 845-8[PubMed]
  • 17. Chopra A, Das P, Rai A, Kuppuswamy PS, Li X, Huston J, et al. Catatonia as a manifestation of tacrolimus-induced neurotoxicity in organ transplant patients: a case series. Gen Hosp Psychiatry. 2012; 34(2): 209000000000-11[DOI][PubMed]
  • 18. Sierra-Hidalgo F, Martinez-Salio A, Moreno-Garcia S, de Pablo-Fernandez E, Correas-Callero E, Ruiz-Morales J. Akinetic mutism induced by tacrolimus. Clin Neuropharmacol. 2009; 32(5): 293-4[DOI][PubMed]
  • 19. Wu Q, Marescaux C, Wolff V, Jeung MY, Kessler R, Lauer V, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol. 2010; 64(3): 169-77[DOI][PubMed]
  • 20. Saner FH, Nadalin S, Radtke A, Sotiropoulos GC, Kaiser GM, Paul A. Liver transplantation and neurological side effects. Metab Brain Dis. 2009; 24(1): 183-7[DOI][PubMed]
  • 21. Tolou Ghamari Z, Palizban AA, Wendon J, Tredger JM. Pharmacokinetics of tacrolimus on days one or two after liver transplantation. Transplant Med. 2004; 16: 112-6
  • 22. Tolou-Ghamari Z, Palizban A, Tredger J. Modelling Tacrolimus AUC in Acute and Chronic Liver Disease Immediately after Transplant. Jahrg. 2004; 16-11
  • 23. Li CJ, Li L. Tacrolimus in preventing transplant rejection in Chinese patients--optimizing use. Drug Des Devel Ther. 2015; 9: 473-85[DOI][PubMed]
  • 24. Ozbilgin M, Egeli T, Unek T, Ozkardesler S, Avkan-Oguz V, Sagol O, et al. Incidence of Late Acute Rejection in Living Donor Liver Transplant Patients, Risk Factors, and the Role of Immunosuppressive Drugs. Transplant Proc. 2015; 47(5): 1474-7[DOI][PubMed]
  • 25. Nakamura-Yanagidaira T, Takahashi Y, Sano K, Murata T, Hayashi T. Development of spontaneous neuropathy in NF-kappaBp50-deficient mice by calcineurin-signal involving impaired NF-kappaB activation. Mol Vis. 2011; 17: 2157-70[PubMed]
  • 26. Tolou-Ghamari Z, Wendon J, Tredger JM. In vitro pentamer formation as a biomarker of tacrolimus-related immunosuppressive activity after liver transplantation. Clin Chem Lab Med. 2000; 38(11): 1209-11[DOI][PubMed]
  • 27. Tolou-Ghamari Z, Palizban AA, Michael Tredger J. Clinical monitoring of tacrolimus after liver transplantation using pentamer formation assay and microparticle enzyme immunoassay. Drugs R D. 2004; 5(1): 17-22[PubMed]
  • 28. Al Masri O, Fathallah W, Quader S. Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature. Pediatr Transplant. 2008; 12(8): 914-7[DOI][PubMed]
  • 29. Monostory K, Toth K, Kiss A, Hafra E, Csikany N, Paulik J, et al. Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients. Br J Clin Pharmacol. 2015; 80(6): 1429-37[DOI][PubMed]
  • 30. Fujii N, Ikeda K, Koyama M, Aoyama K, Masunari T, Kondo E, et al. Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2006; 83(5): 459-61[DOI][PubMed]
  • 31. Page RL, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother 2005; 39(6): 1109-13[PubMed]
  • 32. Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Fernandes FB, Casarini DE, et al. Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol 2009; 23(1): 137-45[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments